In addition, our data clearly show that although both HIF-1α and HIF-2α are involved in survival promotion, they participate in different ways to regulate cell death pathways in colon cancer cells and point to blockade of HIF-2α-mediated actions alone or in combination with drugs as a compelling approach to improve therapeutic outcomes in advanced CRC. This evidence concerns the gene HIF1A and colonic neoplasm.